Oncology
3 drugs are in development for Metastatic Breast Cancer.
- Companies
- 2
- Clinical trials
- 78
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Breast Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(2)
Phase 1(1)
| Drug | Company |
|---|---|
| OP-3136 | Olema Pharmaceuticals, Inc. (OLMA) |
About this indication
Metastatic Breast Cancer context
Oncology·MeSH: Breast Neoplasms (D001943)
Narrower concept of MeSH descriptor Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Breast Cancer?
BioSniper tracks 3 drugs in development for Metastatic Breast Cancer across 2 companies.
How many clinical trials target Metastatic Breast Cancer?
There are 78 clinical trials targeting Metastatic Breast Cancer tracked by BioSniper.
What is the prevalence of Metastatic Breast Cancer?
The estimated prevalence of Metastatic Breast Cancer is approximately 287.0 per 100,000 population.